Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer

Reungwetwattana, T; Rohatgi, N; Mok, TS; Prabhash, K

Mok, TS (corresponding author), Chinese Univ Hong Kong, State Key Lab Translat Oncol, Dept Clin Oncol, Hong Kong, Peoples R China.

EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021; 6 (3): 161

Abstract

Introduction: Dacomitinib is a second-generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI). Recent results from ARCHER 105......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索